Latest Leadership And Governance News

JB Hi-Fi delivered a solid FY26 with record revenue and profit growth, declaring a 22.5% higher dividend and advancing its net-zero emissions goal.

F&C Investment Trust delivered a 12.4% net asset value total return for H1 2026, narrowly trailing the FTSE All-World Index. The trust declared a 0.99p interim dividend and announced a chairman succession as it navigates AI-led market dynamics and geopolitical volatility.

Yugo Metals is pushing ahead with exploration in Bosnia and Herzegovina, backed by a fresh $5 million capital raise and encouraging early gold results at its Sinjakovo Project. Preparations are underway for new drilling at Cajnice, while the company continues to expand its footprint in battery and base metals.

Monvia Limited, an Australian SaaS provider for life insurers, is seeking to raise $17.5 million via an IPO on the ASX. The funds will support redemption of preference shares and fuel growth in existing and new markets.

ikeGPS Group Limited reported a 33% surge in subscription revenue to NZ$19.2 million for FY26, driven by AI-powered product innovation and expanding adoption among North American utilities. The company achieved positive underlying EBITDA in March and ended the year with NZ$33 million cash and no debt.

Pacific Edge reported a $35.8 million loss in FY26 amid a 47% revenue drop following Medicare coverage loss, but a draft Medicare policy and $36.1 million capital raise set the stage for recovery.

EROAD Limited reported stable FY26 revenue of NZD 195 million amid a $134.7 million North American impairment, unveiling a strategic reset centred on ANZ growth and its expanding electronic Road User Charges platform.

WasteCo Group’s Chair Roger Gower will resign in July 2026, with Sean Joyce stepping up as Chair amid ongoing CEO recruitment and operational upgrades.

Elanor Investors Group has finalised a $125 million recapitalisation that slashes its cost of capital and reduces debt, setting the stage for a leaner, capital-light funds management model and imminent ASX reinstatement.

Promisia Healthcare reported a 58% jump in underlying EBITDAF to $6.6 million for FY26, driven by improved occupancy and operational upgrades. The company introduced a dividend policy tied to operating free cash flow, signalling confidence in sustained cash generation.

Amplia Therapeutics reported encouraging mature data from its ACCENT pancreatic cancer trial showing improved survival and response rates with narmafotinib. The company raised $27.5 million to fund development and manufacturing scale-up, while discontinuing a parallel trial due to chemotherapy toxicity.

TruScreen Group reported a 42% increase in FY2026 sales driven by new market entries including India and Indonesia, alongside launching a large-scale cervical cancer screening program in Vietnam and submitting major UNITAID proposals.